Cadila gets USFDA nod to sell generic anti-viral drug
New Delhi : Drug firm Cadila Healthcare has received approval from the US health regulator USFDA to market anti-viral generic in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Acyclovir capsules USP 200 mg, Cadila Healthcare said in a regulatory filing.
The drug will be produced at the company's formulations manufacturing facility at SEZ, Ahmedabad, it added.
The Ahmedabad-based Zydus Group has now 100 approvals from the USFDA. It has so far filed over 280 Abbreviated New Drug Applications (ANDAs) with the US drug regulator since the commencement of the filing process in FY 2003-04.
Cadila Healthcare shares were trading 1.22 per cent down, at Rs 315 apiece on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd